Pfizer Reports Phase 3 Data for Avacopan in Hepatitis C

Pfizer today announced Phase 3 results for avacopan in patients with hepatitis C. The study demonstrated that avacopan reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of hepatitis C and support the continued development of avacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.